Evogene Ltd.

Regulatory Filings • Jan 28, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2020

Commission File Number: 001-36187

EVOGENE LTD. (Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Evogene Investor Presentation – January 2020.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 28, 2020 By: /s/ Dorit Kreiner

EVOGENE LTD. (Registrant)

Dorit Kreiner Chief Financial Officer

2

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1 Evogene Investor Presentation – January 2020.

INVESTOR PRESENTATAION January 2020

SAFE HARBOR STATEMENT

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements. Evogene claims the protection of the safe harbor for forwardlooking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action. contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

3 AGENDA What we do Evolution of Evogene Target markets Corporate structure & activities Summary Technological approach

WHAT WE DO

Evogene is a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications

THE CHALLENGE IN PRODUCT DEVELOPMENT COMMON PRACTICE

Limited 'next generation' products in pipelines

EVOGENE'S SOLUTION CANDIDATES WITH THE HIGHEST PROBABILITY OF SUCCESS

EVOGENE'S SOLUTION CANDIDATES WITH THE HIGHEST PROBABILITY OF SUCCESS

CPB PLATFORM - WHY NOW? HARNESSING THE POWER OF THE COMPUTATIONAL REVOLUTION

Evogene's CPB platform leveraging the revolutions in Big Data and Artificial Intelligence together with a deep understanding of biology, to successfully address multiple product attributes at the beginning of the discovery process, rather than one at a time during the development phase

FIELDS OF DEVELOPMENT

TARGET MARKETS & FIELDS OF ACTIVITY

11

FROM A DIVISION TO A SUBSIDIARY

14 COMPANY STRUCTURE Field Collaborations Bio Stimulants Bio Pesticides ( i ) Yield, ABST (ii) Plant Disease (iii) Insect Control ( i ) Stable high yield of specific compounds (ii) Stable high yield of total compounds ( i ) Immuno - oncology (ii) MDRO (iii) GI related disorders Herbicides Insecticides Castor Seeds & Growth protocol Pipeline

16 COMPANY STRUCTURE Field Collaborations Bio Stimulants Bio Pesticides ( i ) Yield, ABST (ii) Plant Disease (iii) Insect Control ( i ) Stable high yield of specific compounds (ii) Stable high yield of total compounds ( i ) Immuno - oncology (ii) MDRO (iii) GI related disorders Herbicides Insecticides Castor Seeds & Growth protocol Pipeline

CANONIC

Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel - November 6, 2019 - Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

Canonic achieved an important milestone with the import of a genetically diverse seed collection of cannabis lines originating from different territories. These seeds were specifically selected to be the foundation of Canonic's advanced breeding program and product pipeline consisting of MetaYield - medical cannabis products with a stable increase of total plant active compounds, and Precise product line - medical cannabis with a stable increase of specific plant active compounds.

18 COMPANY STRUCTURE Field Collaborations Bio Stimulants Bio Pesticides ( i ) Yield, ABST (ii) Plant Disease (iii) Insect Control ( i ) Stable high yield of specific compounds (ii) Stable high yield of total compounds ( i ) Immuno - oncology (ii) MDRO (iii) GI related disorders Herbicides Insecticides Castor Seeds & Growth protocol Pipeline

BIOMICA

Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program

The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials

Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.

Biose Industrie is a drug-GMP certified manufacturer of bacteria-based APIs and clinical and commercial products. Biomica engaged with Biose for the scale-up development and GMP production of a clinical batch of its drug candidates.

MILESTONE ROADMAP

"aqPlenus	A new collaboration focusing on pre "leads' candidates from the herbicide program	"aqPlenus	First 'lead' licensing agreement from the herbicide program
BIOMICA	Extended pre-clinical study in oncology program; scale-up process and first GMP production of drug candidates	BIOMICA	Proof of concept, first in man study, in the oncology program
CANONIC	Demonstrate first desired cannabis trait (e.g yield or specific cannabinoid)	CANONIC	Pre-commercial activity with first cannabis variety towards commercialization in early 2022
casterra	Initial commercial castor seed sales in Brazil	casteria	Ramp-up commercial castor seed sales to 3K hectares
lavie bio	File for regulatory approval for a wheat bio- stimulant product, and pre-commercialization phase advancement	lavie bio	Receive regulatory approval and initiation of pre-commercial activities (pilots with farmers) as preparation for product launch in 2022
	2020		2021

SUMMARY

WHAI WE DO	CORPORATE SIRUCTURE -
We leverage computational biology to design novel products for life-science-based industries including human health, agriculture, and industrial applications.	Evogene and the CPB platfo at the heart of a group of subsidiaries, each focused in different life-science based
OUR TECHNOLOGY - THE CPB PLATFORM	markets, with exclusive acce
Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at 'Stage Zero'.	to the CPB platform for thei field of activity, providing th main competitive advantage for their product developme
CPB CAPABILITIES FOR PREDICTION OF INNOVATION	pipeline.
· Genetic elements - controlling desired biological processes · Small molecules - active ingredients for chemical based products · Microbes - active ingredients for microbial based products	FINANCIAL FUNDAMENTA
TARGET MARKETS AND CURRENT ACTIVITIES	· Cash position - \$ 52.1 M
· Agriculture - Ag-Chemicals, Seed Traits, Ag-Biologicals · Human Health - Human Microbiome, Drug Discovery, Medical Cannabis · Industrial Applications - Castor oil	(Sep. 30, 2019), no debt · Listed on TASE (2007) an NASDAQ (2013)

MAIN COLLABORATIONS WITH WORLD-LEADING COMPANIES -

---------- (BASER) (BASER) EVA 2 21CL

evogene ______________________________________________________________________________________________________________________________________________________________________

orm n ess ir neir e ent

LS

• nd

21

THANK YOU

23 Annex I: Financial Fundamentals

KEY FINANCIALS - BALANCE SHEET

30.09.2019	31.12.2018	Key Points:
53,828	55,488	■ Cash position: ~52 million USD as of 30.09.2019
22,615 *	3,206	No debt ■
76,443	58,694
4,729	5,431	E Estimated net cash usage for 2019: \$16-\$18 million
5,580	2,957	■ Listed on TASE (2007) and NASDAQ (2013)
Equity attributable to equity holders of 56,090	50,053
10,044	253	*17,255 thousand dollars attributed to intangible assets (net) following Corteva's
Total Liabilities & Shareholders Equity 76,443	58,694	investment in Lavie Bio